Clinical Trials Logo

Still Disease, Juvenile-Onset clinical trials

View clinical trials related to Still Disease, Juvenile-Onset.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03932344 Completed - Clinical trials for Still Disease, Juvenile Onset

Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

Start date: April 10, 2019
Phase:
Study type: Observational

The purpose of the study is to evaluate and characterize long-term safety of Kineret when used in standard clinical practice to treat patients with systemic juvenile idiopathic arthritis (SJIA). The study will be based on already available data from the Pharmachild juvenile idiopathic arthritis (JIA) registry which holds the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP) study seal.

NCT ID: NCT00420251 Completed - Clinical trials for Juvenile Idiopathic Arthritis

Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis

Start date: March 1996
Phase: Phase 3
Study type: Interventional

Growth retardation is well known in patients with severe forms of juvenile idiopathic arthritis. Especially those who were under additional treatment with glucocorticoids for high disease activity. The hypothesis is, that treatment with growth hormone can, at leat in part, overcome growth hormone resistance state and increase final height. In a controlled study we follow patients with juvenile idiopathic arthritis with and without growth hormone treatment until final height. Additionally, we are interested in bone density development in those treated with growth hormone.